Published in J Am Coll Radiol on December 14, 2012
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys (2004) 3.42
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys (2012) 2.12
The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys (2012) 2.10
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys (2013) 2.02
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol (2005) 1.98
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys (2007) 1.87
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer (2011) 1.70
Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.69
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer (2003) 1.56
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys (2012) 1.54
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol (2009) 1.34
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database. J Oncol Pract (2011) 1.31
A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood (2011) 1.28
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol (2005) 1.28
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys (2008) 1.22
Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.20
Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist (2013) 1.20
A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol (2012) 1.19
Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res (2004) 1.15
Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol (2012) 1.11
Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys (2005) 1.11
Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol (2014) 1.08
Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. Int J Radiat Oncol Biol Phys (2012) 1.06
Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev (2012) 1.06
Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol (2013) 1.05
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys (2007) 1.04
Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle (2008) 1.03
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res (2006) 1.02
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys (2012) 1.02
The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer (2012) 1.01
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. J Neurooncol (2011) 0.98
Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res (2005) 0.97
Fractionated stereotactic radiotherapy for the treatment of optic nerve sheath meningiomas: preliminary observations of 33 optic nerves in 30 patients with historical comparison to observation with or without prior surgery. Neurosurgery (2002) 0.96
Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys (2011) 0.96
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys (2008) 0.95
Combination of longitudinal and circumferential three-dimensional esophageal dose distribution predicts acute esophagitis in hypofractionated reirradiation of patients with non-small-cell lung cancer treated in stereotactic body frame. Int J Radiat Oncol Biol Phys (2005) 0.95
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol (2011) 0.94
Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys (2003) 0.94
Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys (2005) 0.94
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst (2012) 0.94
Prognostic factors in non-small cell lung cancer. Semin Surg Oncol (2003) 0.93
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis (2008) 0.93
Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys (2012) 0.93
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther (2009) 0.93
Esophagitis, treatment-related toxicity in non-small cell lung cancer. Rev Recent Clin Trials (2012) 0.93
On the merits and limitations of whole-brain radiation therapy. J Clin Oncol (2012) 0.93
Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev (2013) 0.92
Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics (2012) 0.91
Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. Am J Clin Oncol (2013) 0.91
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. Ultrasound Med Biol (2002) 0.91
Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy (2005) 0.91
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys (2006) 0.91
Glycerol rhizotomy versus gamma knife radiosurgery for the treatment of trigeminal neuralgia: an analysis of patients treated at one institution. Int J Radiat Oncol Biol Phys (2005) 0.91
Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos. BMC Dev Biol (2010) 0.91
Reliability of EUCLIDIAN: an autonomous robotic system for image-guided prostate brachytherapy. Med Phys (2011) 0.90
Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol (2013) 0.90
Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2012) 0.90
Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol (2012) 0.89
Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res (2004) 0.89
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer (2013) 0.89
Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Front Oncol (2013) 0.89